Evidence map›Paper›PMID 36497345›Full record

ArticleCancers2022

Proton Beam Therapy for Pediatric Tumors of the Central Nervous System-Experiences of Clinical Outcome and Feasibility from the KiProReg Study.

Sarah Peters, Sabine Frisch, Annika Stock, Julien Merta, Christian Bäumer, Christoph Blase, Eicke Schuermann, Stephan Tippelt, Brigitte Bison, Michael Frühwald and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Sarah PetersWest German Proton Therapy Center Essen (WPE), University Hospital Essen, 45147 Essen, Germany.
Sabine FrischWest German Proton Therapy Center Essen (WPE), University Hospital Essen, 45147 Essen, Germany.
Annika StockDepartment of Neuroradiology, University Hospital Wuerzburg, 97080 Wuerzburg, Germany.ORCID 0000-0003-0148-4652
Julien MertaWest German Proton Therapy Center Essen (WPE), University Hospital Essen, 45147 Essen, Germany.
Christian BäumerWest German Proton Therapy Center Essen (WPE), University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0003-0512-1146
Christoph BlaseAnästhesieNetz Rhein-Ruhr, Westenfelder Str. 62/64, 44867 Bochum, Germany.
Eicke SchuermannDepartment of Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, 45147 Essen, Germany.
Stephan TippeltDepartment of Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0001-8791-9914
Brigitte BisonDiagnostic and Interventional Neuroradiology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
Michael FrühwaldPediatric and Adolescent Medicine, Swabian Childrens Cancer Center, University Medical Center Augsburg, 86156 Augsburg, Germany.ORCID 0000-0002-8237-1854
Stefan RutkowskiDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Gudrun FleischhackDepartment of Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0001-5714-007X
Beate TimmermannWest German Proton Therapy Center Essen (WPE), University Hospital Essen, 45147 Essen, Germany.
Essen University Hospital · DEGerman Cancer Society · DEUniversität Hamburg · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Augsburg · DEUniversity of Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As radiotherapy is an important part of the treatment in a variety of pediatric tumors of the central nervous system (CNS), proton beam therapy (PBT) plays an evolving role due to its potential benefits attributable to the unique dose distribution, with the possibility to deliver high doses to the target volume while sparing surrounding tissue. Children receiving PBT for an intracranial tumor between August 2013 and October 2017 were enrolled in the prospective registry study KiProReg. Patient's clinical data including treatment, outcome, and follow-up were analyzed using descriptive statistics, Kaplan-Meier, and Cox regression analysis. Adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 before, during, and after PBT. Written reports of follow-up imaging were screened for newly emerged evidence of imaging changes, according to a list of predefined keywords for the first 14 months after PBT. Two hundred and ninety-four patients were enrolled in this study. The 3-year overall survival of the whole cohort was 82.7%, 3-year progression-free survival was 67.3%, and 3-year local control was 79.5%. Seventeen patients developed grade 3 adverse events of the CNS during long-term follow-up (new adverse event

Indexed as

adverse eventsbrain cancerchildhood cancerimaging changesproton beam therapy

Identifiers

PMID36497345
PMCPMC9737072
OpenAlexW4310147683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.